Skip to main content

Table 1 Baseline characteristics of enrolled patients

From: Differences in clinical outcomes according to the time interval between the bridge to surgery stenting and surgery for left-sided malignant colorectal obstruction

  Total
n (%)
Bridging interval P-value
Group 1
≤2 weeks
n (%)
Group 2
2–3 weeks
n (%)
Group 3
>3 weeks
n (%)
Overall ≤2 weeks vs. 2–3 weeks 2–3 weeks vs. >3 weeks ≤2 weeks vs. >3 weeks
Number of patients 148 47 43 58  
Male sex 86 (58.1) 28 (59.6) 31 (72.1) 27 (46.6) 0.037 0.269 0.014 0.239
Age, median years (IQR years) 68.0 (58.0–77.0) 68.0 (55.0–78.0) 66.0 (56.0–76.0) 70.5 (61.8–77.0) 0.313 0.545 0.122 0.427
BMI, median kg/m2 (IQR kg/m2) 22.2 (20.0–24.9) 22.8 (20.6–25.0) 22.0 (20.2–24.8) 22.2 (19.3–25.0) 0.846 0.634 0.844 0.620
ASA score      0.119 0.679 0.066 0.253
 ASA 1–2 132 (89.2) 43 (91.5) 43 (95.3) 48 (82.8)     
 ASA 3–4 16 (10.8) 4 (8.5) 2 (4.7) 10 (17.2)     
Previous abdominal surgery 43 (29.1) 12 (25.5) 13 (30.2) 18 (31.0) 0.829 0.645 1.000 0.665
Primary tumor location      0.378 0.567 0.510 0.174
 Splenic flexure 9 (6.1) 4 (8.5) 1 (2.3) 4 (6.9)     
 Descending colon 15 (10.1) 2 (4.3) 4 (9.3) 9 (15.5)     
 Sigmoido-descending junction 11 (7.4) 2 (4.3) 4 (9.3) 5 (8.6)     
 Sigmoid colon 75 (50.7) 28 (59.6) 24 (55.8) 23 (39.7)     
 Recto-sigmoid junction 38 (25.7) 11 (23.4) 10 (23.3) 17 (29.3)     
Preoperative serum CEA, median ng/ml (IQR ng/ml) (n=146) 5.7 (3.2–13.6) 7.8 (4.3–15.3) 4.9 (2.5–9.8) 5.2 (2.7–11.7) 0.127 0.067 0.920 0.089
Adjuvant chemotherapy 116 (78.4) 38 (80.9) 35 (81.4) 43 (74.1) 0.633 1.000 0.475 0.488
Interval from SEMS to operation, median days (IQR days) 19.0 (12.0–25.8) 10.0 (8.0–12.0) 18.0 (17.0–20.0) 28.0 (24.0–32.3) <0.001 <0.001 <0.001 <0.001
Pathologic results  
 T stage   0.894 1.000 0.832 0.664
  1 1 (0.7) 1 (2.1) 0 (0.0) 0 (0.0)     
  3 101 (68.2) 32 (68.1) 30 (69.8) 39 (67.2)     
  4 46 (31.1) 14 (29.8) 13 (30.2) 19 (32.8)     
 N stage      0.139 0.037 0.139 0.756
  0 66 (44.6) 18 (38.3) 24 (55.8) 24 (41.4)     
  1 54 (36.5) 22 (46.8) 9 (20.9) 23 (39.7)     
  2 28 (18.9) 7 (14.9) 10 (23.3) 11 (19.0)     
 Overall stage      0.205 0.138 0.164 0.842
  2 66 (44.6) 18 (38.3) 24 (55.8) 24 (41.4)     
  3 82 (55.4) 29 (61.9) 19 (44.2) 34 (58.6)     
Tumor size, median cm (IQR cm) 6.5 (5.5–7.5) 6.0 (5.0–6.5) 7.0 (6.0–8.0) 7.2 (7.0–8.0) <0.001 <0.001 0.329 <0.001
Histologic grade      0.225 0.105 0.648 0.501
 WD/MD 143 (96.6) 47 (100.0) 40 (93.0) 56 (96.6)     
 PD/Mucinous 5 (3.4) 0 (0.0) 3 (7.0) 2 (3.4)     
Lymphovascular invasion 39 (26.4) 11 (23.4) 15 (34.9) 13 (22.4) 0.316 0.253 0.184 1.000
Perinueral invasion 97 (65.5) 29 (61.7) 29 (67.4) 39 (67.2) 0.841 0.661 1.000 0.682
  1. IQR Interquartile range, BMI Body mass index, ASA American Society of Anesthesiologists, CEA Carcinoembryonic antigen, WD Well-differentiated, MD Moderately differentiated, PD Poorly differentiated